Clinical trial using MAF for hospitalized COVID-19 patients in Ukraine

In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment.

In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment. The US FDA in PreIND 151946 meeting response recommended a small proof of concept (POC) study as the initial step prior to the large-scale trial be run. The US FDA indicated recommendations including the major study endpoints addressing the investigation of MAF Capsules efficacy as a potential new drug was implemented in the proposed study design.

The recommended efficacy endpoints were also implemented in the open-label randomized clinical trial that started in Ukraine in November 2020 to assess the efficacy and safety of dietary supplements MAF Capsules, 148 mg and M Capsules, 148 mg in addition to standard of care (SOC) compared with SOC in the treatment of hospitalized non-critical COVID-19 patients.

Summary of preliminary results of clinical study

The ongoing interim study results showed a decrease in all-cause mortality and necessity of oxygen supply, as the mortality was 4/15 in the control group, vs 0/16 and 1/17 of currently enrolled patients in the MAF Capsules and M Capsules groups respectively. The mean duration of supplemental oxygen was 8.5 days in the control group, vs 4.1 and 5.1 days in the MAF Capsules and M Capsules groups respectively.

 

MAF Capsules, which is under investigational new drug process, is a dietary supplement that targets guts mucosal immunity to modulate macrophages functionality, limiting epithelial damage, and controlling inflammation response during COVID-19.

 

Clinical trial groups:

  • Control group
  • MAF Capsules (colostrum MAF) group
  • M Capsules (whey MAF) group

Patients randomized 1:1:1 to:

  1. SOC (standard of care)
  2. SOC plus MAF Capsules (148 mg, 3 caps. TID for 14 days)
  3. SOC plus M Capsules (148 mg, 3 caps. TID for 14 days)

As compared to the control, both MAF groups showed a clear trend in decreasing mortality

 

  • No adverse events
  • Decrease in the mortality rate
  • Decrease in necessity and duration of supplemental oxygen
  • Decrease in time to recovery
  • Decrease in time until hospital discharge
  • Preventing of respiratory failure
  • Restoring the base-line decreased lymphocytes count

     

6-Jan-2021
error: Content is protected !!